Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries

Table 3 Outlets with specific anti-malarial categories as a percentage of outlets with at least one anti-malarial in stock, by sector¹

	Benin		DRC		Madagascar		Nigeria		Uganda		Zambia
	Public/Not- for-Profit	Private	Public/Not- for-Profit	Private	Public/Not- for-Profit	Private	Public/Not- for-Profit	Private	Public/Not- for-Profit	Private	Public/Not- for-Profit	Private
	N=212	N=632	N=134	N=1, 240	N=560	N=1, 854	N=249	N=1, 864	N=534	N=691	N=176	N=259
Any ACT	71.4 ^a	6.4 ^b	84.4 ^a	52.7 ^b	92.2 ^a	8.4 ^b	60.6 ^a	36.7 ^a	81.5 ^a	20.1 ^b	82.2 ^a	19.3 ^b
First-line quality-assured ACT	66.4 ^a	5.7 ^b	75.8 ^a	24.5 ^b	91.9 ^a	7.9 ^b	49.2 ^a	25.3 ^b	73.4 ^a	7.8 ^b	81.5 ^a	16.3 ^b
Quality-assured ACT	66.4 ^a	5.9 ^b	78.7 ^a	29.0 ^b	91.9 ^a	8.1 ^b	49.2 ^a	26.1 ^a	73.4 ^a	8.1 ^b	81.5 ^a	16.3 ^b
Non-Quality-assured ACT	5.1 ^a	0.5 ^b	5.6 ^a	23.6 ^b	0.3 ^a	0.3 ^a	11.5 ^a	10.5 ^a	9.3 ^a	15.2 ^a	0.8 ^a	2.9 ^b
Any non-artemisinin therapy	96.7 ^a	99.7 ^b	93.8 ^a	97.8 ^a	36.3 ^a	99.3 ^b	81.7 ^a	98.2 ^b	68.6 ^a	99.6 ^b	98.4 ^a	98.8 ^a
Chloroquine	9.3 ^a	82.1 ^b	0.0 ^a	4.0 ^b	1.6 ^a	95.5 ^b	57.7 ^a	91.9 ^b	15.5 ^a	61.0 ^b	0.0 ^a	21.7 ^b
SP	51.2 ^a	15.8 ^b	66.9 ^a	57.9 ^a	22.0 ^a	9.2 ^a	62.7 ^a	78.3 ^a	49.9 ^a	68.2 ^a	65.5 ^a	80.2 ^a
Quinine	92.5 ^a	24.0 ^b	85.7 ^a	84.3 ^a	23.3 ^a	10.7 ^a	20.0 ^a	9.2 ^a	59.0 ^a	82.9 ^b	89.1 ^a	16.8 ^b
Quinine injection	60.0 ^a	8.0 ^b	65.6 ^a	40.7 ^b	20.9 ^a	9.5 ^a	19.0 ^a	0.6 ^b	56.4 ^a	32.6 ^a	51.2 ^a	8.7 ^b
Oral artemisinin monotherapy	3.8 ^a	0.7 ^a	10.2 ^a	40.5 ^b	0.0 ^a	< 0.1 ^a	4.1 ^a	45.1 ^b	1.3 ^a	13.3 ^b	1.1 ^a	2.5 ^a

¹Statistical comparisons conducted across outlet types, within countries. Statistical difference is labelled with a superscript, a or b. Proportions with different letters in their superscripts differ significantly from one another within countries (p < 0.05 for all tests).

ISSN: 1475-2875